Drug Profile
YH 26136
Alternative Names: YH 26136Latest Information Update: 28 Dec 2021
Price :
$50
*
At a glance
- Originator Yuhan
- Class Antihyperlipidaemics; Antithrombotics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Dyslipidaemias; Thrombosis
Most Recent Events
- 28 Dec 2021 No recent reports of development identified for preclinical development in Dyslipidaemias in South Korea
- 28 Dec 2021 No recent reports of development identified for preclinical development in Thrombosis in South Korea
- 27 Nov 2017 Preclinical trials in Dyslipidaemias in South Korea before November 2017 (Yuhan pipeline, November 2017)